Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma - PubMed (original) (raw)

. 2019 Oct;60(10):2558-2562.

doi: 10.1080/10428194.2019.1585836. Epub 2019 Mar 8.

Adam Pagenkopf 2 3, Muhammad Umair Mushtaq 2 3, Ashley M Cunningham 4, Evan Flietner 2 3, Zachary Morrow 2 3, Athanasios Papadas 2 3, Chelsea Hope 2 3, Catherine Leith 5, Peiman Hematti 2 3, Parameswaran Hari 1, Natalie S Callander 2 3, Fotis Asimakopoulos 2 3

Affiliations

Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma

Binod Dhakal et al. Leuk Lymphoma. 2019 Oct.

No abstract available

PubMed Disclaimer

Conflict of interest statement

CONFLICTS

None of the authors has any relevant conflicts to declare.

Figures

Figure 1.

Figure 1.

(A), Representative photomicrographs of post-ASCT bone marrow biopsies stained with an antibody detecting VCAN proteolysis (anti-DPEAAE neoepitope) (top) and an anti-CD8 antibody (bottom). hpf= high-power field. (B) Box-and-whisker plots demonstrating the distribution of CD8+ count per hpf according to VCAN proteolysis intensity. (C) Kaplan-Meier curves demonstrating overall survival (OS, p= 0.003) (left) and progression-free survival (PFS, p=0.054) (right) according to VCAN proteolysis intensity: low (1+) and moderate/high (2+ and 3+ intensity combined).

References

    1. Dhakal B, Szabo A, Chhabra S, et al. . Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. JAMA Oncol 2018;4:343–350. -PMC -PubMed
    1. Guillerey C, Harjunpaa H, Carrie N, et al. . TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma. Blood 2018;132:1689–1694. -PubMed
    1. Minnie SA, Kuns RD, Gartlan KH, et al. . Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade. Blood 2018;132:1675–1688. -PubMed
    1. Chung DJ, Pronschinske KB, Shyer JA, et al. . T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy. Cancer Immunol Res 2016;4:61–71. -PMC -PubMed
    1. Suen H, Brown R, Yang S, et al. . Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade. Leukemia 2016;30:1716–1724. -PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources